

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	Unassigned
Filing Date	April 16, 2004
First Named Inventor	Ashok TEHIM et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-40

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/KS/	A1	4,012,495		Schmiechen, et al.	03-15-1977	
/KS/	A2	4,193,926		Schmiechen, et al.	03-18-1980	
/KS/	A3	4,219,551		Seidemann et al.	08-26-1980	
/KS/	A4	5,846,514		Foster et al.	12-08-1998	
/KS/	A5	5,539,111		Petzoldt, et al.	07-23-1996	
/KS/	A6	5,814,651		Duplantier, et al.	09-29-1998	
/KS/	A7	5,935,978		Fenton, et al.	08-10-1999	
/KS/	A8	6,136,821		Hersperger	10-24-2000	
/KS/	A9	6,258,833		Martins, et al.	07-10-2001	
/KS/	A10	6,372,777		Martins, et al.	04-16-2002	
/KS/	A11	6,334,997		Foster et al.	1-1-2002	
/KS/	A12	6,403,597		Wilson et al.	06-2002	
/KS/	A13	6,423,710		Martins, et al.	07-23-2002	
/KS/	A14	6,495,154		Tam, et al.	12-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)				
/KS/	B1	WO	01/68600	A2	Lauener et al.	09-20-2001		
/KS/	B2	WO	02/45749	A2	Filbin et al.	06-13-2002		
/KS/	B3	WO	92/19594		Bender et al.	11-12-1992		
/KS/	B4	WO	93/07141	A1	Bender et al.	04-15-1993		
/KS/	B5	WO	93/25517	A1	Beeley et al.	12-23-1993		
/KS/	B6	WO	94/14742	A1	Warrellow et al.	07-07-1994		
/KS/	B7	WO	95/28926	A1	Wachtel et al.	11-02-1995		
/KS/	B8	WO	95/35282		Head et al.	12-28-1995		
/KS/	B9	WO	97/25312		Schmiechen, et al.	07-17-1997		
/KS/	B10	WO	98/58901	A1	Ina et al.	12-30-1998		Abstr.
/KS/	B11	JP	64-72415			3-17-1998		

Examiner
Signature

/Kamal Saeed/

Date
Considered

05/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	Unassigned
Filing Date	April 16, 2004
First Named Inventor	Ashok TEHIM
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-40

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/KS/	C1	Nagakura et al., "Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats," <i>British Journal of Pharmacology</i> , (2002) 135, 1783-1793	
/KS/	C2	Keller et al., "Synthesis and Structure-Activity Relationship of N-Arylrolipram Derivatives as Inhibitors of PDE4 Isozymes," <i>Chem. Pharm. Bull.</i> , 49(8) 1009-1017 (2001)	
/KS/	C3	Martin, "PDE4 inhibitors – A review of the recent patent literature," <i>Idrugs</i> , 2001 4 (3):312-338	
/KS/	C4	Wang et al., "Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D," <i>Biochemical and Biophysical Research Communications</i> , 234, 320-324 (1997)	
/KS/	C5	Meyers et al., "The Synthesis of Aracemic 4-Substituted Pyrrolidinones and 3-Substituted Pyrrolidines. An Asymmetric Synthesis of (-)-Rolipram," <i>J. Org. Chem.</i> , 1993, 58, 36-42	
/KS/	C6	Crossland, J., "Rolipram," <i>Drugs Of The Future</i> , Vol. 13, No. 1, 1988	
/KS/	C7	Langlois et al., "Synthesis of the Novel Antidepressant (R)-(-)-Rolipram," <i>Synthetic Communications</i> , 27 (18), 3133-3144 (1997)	
/KS/	C8	Robichaud et al., "Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret," <i>Neuropharmacology</i> , 38 (1999) 289-297	
/KS/	C9	Houslay et al., "The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions," <i>Advance in Pharmacology</i> , Volume 44, pp. 225-342 (1998)	
/KS/	C10	Zhang et al., "Inhibition Of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NMDA Receptor Antagonism," <i>Neuropsychopharmacology</i> , 2000, 23, 198-204	
/KS/	C11	Zhang et al., "Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats," <i>Psychopharmacology DOI</i> , 10.1007/s002130000414 (2000)	
/KS/	C12	Barad et al., "Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory," <i>Proc. Natl. Acad. Sci., USA</i> , Volume 95, pp. 15020-15025, December 1998	
/KS/	C13	Dennitz et al., "Enantiodivergent Synthesis of (R)- and (S)-Rolipram," <i>Molecules</i> , 1998, 3, 107-119	
/KS/	C14	Osby et al., "Rapid and Efficient Reduction of Aliphatic Nitro Compounds to Amines," <i>Tetrahedron Letters</i> , Volume 26, No. 52, pp. 6413-6416, 1985	
/KS/	C15	Küstner et al., "Influence of temperature on the enantioseparation of rolipram and structurally related racemates on Chiralcel-OD," <i>Journal of Chromatography A</i> , 737, (1996) 333-337	
/KS/	C16	Christensen et al., "1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma," <i>J. Med. Chem.</i> , 1998, 41, 821-835	
/KS/	C17	Krause et al., "Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences," <i>Xenobiotica</i> , 1988, Vol. 18, No. 5, 561-571	
/KS/	C18	Lourenco et al., "Characterization of R-[1¹C]rolipram for PET imaging for phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats," <i>Nuclear Medicine and Biology</i> , 28 (2001) 347-358	
/KS/	C19	Egawa et al., "Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats," <i>Jpn J Pharmacol</i> , 1997 Nov, 75 (3): 275-81	
/KS/	C20	Schmiechen et al., "Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase," <i>Psychopharmacology</i> , (Berl) 1990; 102 (1): 17-20	
/KS/	C21	Marivet et al., "Inhibition of Cyclic Adenosine-3',5'-monophosphate Phosphodiesterase from Vascular Smooth Muscle by Rolipram Analogues," <i>J. Med. Chem.</i> , 1989, 32, 1450-1457	
/KS/	C22	Morgan et al., "Biochemical Pharmacology (1993)", 45(12), 2373-80, pgs 23-27, CAS Abstract Only,	

Examiner Signature

/Kamal Saeed/

Date Considered

05/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1448A/PTO				Complete if Known	
				Application Number	Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	April 16, 2004
				First Named Inventor	Ashok TEHIM et al.
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	MEMORY-40
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
/KS/		5,128,358		Saccomano et al.	7/7/1992

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/KS/		WO	92/19594			11/12/1992		
/KS/		WO	91/16303			10/31/1991		
/KS/		FR	2 264 531			10/17/1975		
/KS/		WO	95/28926			11/2/1995		
/KS/		WO	93/07141			4/15/1993		
/KS/		WO	03/032981			4/24/2003		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KS/		International Search Report and The Written Opinion from International Patent application PCT/US2004/011765	
/KS/		Japan Patent Abstract No. 09 221 423 dated 2/14/1996	
/KS/		Michel C. Marivet, et al., "Inhibition of Cyclic Adenosine-3',5'-monophosphate Phosphodiesterase from Vascular Smooth Muscle by Rolipram Analogues", J. Med. Chem. (1989), Vo. 32, pgs 1450-1457	

Examiner Signature	/Kamal Saeed/	Date Considered	05/29/2007
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+

+

JUN 02 1964

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

of

Education Number

Complete if Known

Unassigned

Filing Date

April 16 ,2004

First Named Inventor

Ashok TEHIM

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

MEMORY-40

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

/Kamāl Saeed/

Date Considered

05/29/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.